Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. More Details
+ 3 more risks
Fair value with imperfect balance sheet.
Share Price & News
How has Allena Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ALNA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: ALNA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
7 Day Return
1 Year Return
Return vs Industry: ALNA underperformed the US Biotechs industry which returned 33.8% over the past year.
Return vs Market: ALNA underperformed the US Market which returned 36.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Allena Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StShould You Review Recent Insider Transactions At Allena Pharmaceuticals, Inc. (NASDAQ:ALNA)?
11 months ago | Simply Wall StCould The Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) Ownership Structure Tell Us Something Useful?
1 year ago | Simply Wall StIs Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) A Volatile Stock?
Is Allena Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ALNA ($1.68) is trading below our estimate of fair value ($10.79)
Significantly Below Fair Value: ALNA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ALNA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ALNA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALNA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ALNA is good value based on its PB Ratio (3.5x) compared to the US Biotechs industry average (4.2x).
How is Allena Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALNA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ALNA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ALNA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if ALNA's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if ALNA's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ALNA is forecast to be unprofitable in 3 years.
How has Allena Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALNA is currently unprofitable.
Growing Profit Margin: ALNA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALNA is unprofitable, and losses have increased over the past 5 years at a rate of 20.3% per year.
Accelerating Growth: Unable to compare ALNA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALNA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-21.9%).
Return on Equity
High ROE: ALNA has a negative Return on Equity (-186.73%), as it is currently unprofitable.
How is Allena Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: ALNA's short term assets ($31.3M) exceed its short term liabilities ($3.9M).
Long Term Liabilities: ALNA's short term assets ($31.3M) exceed its long term liabilities ($9.9M).
Debt to Equity History and Analysis
Debt Level: ALNA's debt to equity ratio (54.2%) is considered high.
Reducing Debt: Insufficient data to determine if ALNA's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALNA has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ALNA has less than a year of cash runway if free cash flow continues to reduce at historical rates of 19.4% each year
What is Allena Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALNA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALNA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALNA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALNA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALNA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Lou Brenner (50 yo)
Dr. Louis Brenner, also known as Lou, M.D., M.B.A., serves as Chief Executive Officer at Allena Pharmaceuticals, Inc since February 1, 2019. He served as the Chief Operating Officer of Allena Pharmaceutica...
CEO Compensation Analysis
Compensation vs Market: Lou's total compensation ($USD2.98M) is above average for companies of similar size in the US market ($USD511.69K).
Compensation vs Earnings: Lou's compensation has increased whilst the company is unprofitable.
|Co-Founder & Chairman of the Board||2yrs||US$787.97k||1.61% |
|Co-Founder & Strategic Adviser||5.83yrs||no data||no data|
|CFO, Principal Financial Officer & Principal Accounting Officer||0.083yr||no data||no data|
|Senior VP of Corporate Development||0.25yr||no data||no data|
|Senior Vice President of Technical Operations||no data||no data||no data|
|Vice President of People & Culture||2.08yrs||no data||no data|
|Chief Medical Officer||0.17yr||no data||no data|
Experienced Management: ALNA's management team is considered experienced (2 years average tenure).
|Co-Founder & Chairman of the Board||2yrs||US$787.97k||1.61% |
|Independent Director||9.42yrs||US$103.59k||0% |
|Independent Lead Director||2yrs||US$133.09k||0.031% |
|Independent Director||4.67yrs||US$101.09k||0% |
|Independent Director||2.67yrs||US$108.59k||0% |
|Independent Director||0.33yr||no data||no data|
|Independent Director||1.83yrs||US$161.24k||0% |
|Board Observer||no data||no data||no data|
Experienced Board: ALNA's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ALNA insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 114.1%.
Allena Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Allena Pharmaceuticals, Inc.
- Ticker: ALNA
- Exchange: NasdaqGS
- Founded: 2011
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$84.422m
- Shares outstanding: 50.25m
- Website: https://www.allenapharma.com
Number of Employees
- Allena Pharmaceuticals, Inc.
- One Newton Executive Park
- Suite 202
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ALNA||NasdaqGS (Nasdaq Global Select)||Yes||Common Shares||US||USD||Nov 2017|
|0PJ||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Nov 2017|
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic,...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/03/01 00:20|
|End of Day Share Price||2021/02/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.